drugset / Trial / NCT07064005

Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.

NCT07064005 ↗

Phase 1 Recruiting 12 enrolled Pravat Mandal Waste Connections Inc · collab
NaSingle-groupOpen-labelPrevention

Summary

This study is designed l to evaluate the effects of GGC oral supplementation in early Parkinson's disease (PD) patients. The main objectives of the study are to evaluate: 1. To study the enrichment of master antioxidant, glutathione (GSH) levels in brain and blood of these PD patients compared to baseline due to GGC supplementation. 2. To study the changes in motor function, cognitive skills in PD patients due to GGC oral supplementation 3. To study impact of GGC on gut health on the PD patients.

Timeline

Start
2026-03-23
Primary completion
2027-09
Completion
2027-11-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Gamma Glutamylcysteine Unknown 400 mg Oral

Indications